SR Biotek Inc

SR Biotek Inc maintains a strong liquidity position, with a current ratio of 1.96 and cash and equivalents amounting to KRW 1,845,882,650. The company's debt-to-equity ratio of 0.26 indicates a conservative capital structure, with long-term debt of KRW 1,425,750,000 and total equity of KRW 5,513,472,940. This suggests a low reliance on external financing and a stable financial foundation. The company's profitability is robust, with a return on equity (ROE) of 35.19% and a return on assets (ROA) of 20.06%. These figures exceed the typical performance metrics for the Personal Products industry, indicating efficient use of equity and assets to generate returns. The operating margin, derived from operating income of KRW 2,589,718,350 on revenue of KRW 37,426,904,370, suggests a healthy margin profile. Geographically and segment-wise, the company's revenue concentration is not explicitly disclosed in the input data. However, the absence of segment-specific breakdowns implies a potentially diversified or consolidated business model. The company's exposure to regional markets is not detailed, but the Personal Products industry is generally less sensitive to macroeconomic volatility compared to other sectors. The company's growth trajectory is supported by a strong free cash flow of KRW 1,378,857,920 and a capital expenditure of KRW -851,304,470. These figures suggest a balance between reinvestment and cash generation, which is favorable for sustaining growth. The outlook for the current fiscal year indicates continued revenue expansion, though specific numeric deltas are not provided in the input data. Risk factors for SR Biotek Inc are currently low, with no immediate liquidity or dilution flags detected in filings or transcripts. The company's low debt load and strong cash position reduce financial risk exposure. Additionally, the absence of dilution potential in the basic shares outstanding (1,664,453) and diluted shares (1,664,453) suggests no near-term pressure from equity issuance. Recent events, including filings and transcripts, do not indicate any material changes in the company's operations or strategic direction. The company appears to be maintaining a stable and predictable business model, with no significant disruptions reported in the latest financial data.